Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases.

Pilch, Kjara S; Späth, Peter Julius; Yuki, Nobuhiro; Wakerley, Benjamin R (2017). Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases. Expert review of neurotherapeutics, 17(6), pp. 579-591. Expert Reviews 10.1080/14737175.2017.1282821

Full text not available from this repository. (Request a copy)

INTRODUCTION Autoimmunity is an important cause of disease both in the central and peripheral nervous systems. Aetiologies and clinical manifestations are complex and heterogeneous. Inappropriate control of complement activation at inappropriate sites has been recognized as a major determinant in several neurological conditions, including Guillain-Barré syndrome and neuromyelitis optica. In each case pathogenesis is thought to be associated with generation of autoantibodies which upon binding guide activation of the complement system to self-tissue. Areas covered: Modulation of the complement system activation at such sites may represent a novel therapeutic approach for treatment of immune-mediated inflammatory conditions. In this review we focus on the therapeutic effects of complement inhibitors in Guillain-Barré syndrome and neuromyelitis optica and highlight recent developments within the field. Expert Commentary: Conventional first line treatment strategies in GBS and NMO have the potential disadvantage of causing widespread immunosuppressive effects. A more targeted approach may therefore be more effective and less disruptive to the immune system, especially in the case of NMO, which requires long term immunosuppression. Modulation of the complement system may hold the key and has already been shown to be of clinical benefit in other non-neurological conditions, including paroxysmal nocturnal hemoglobinuria and hereditary angioedema.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

Späth, Peter Julius

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1473-7175

Publisher:

Expert Reviews

Language:

English

Submitter:

Jana Berger

Date Deposited:

21 Mar 2018 09:20

Last Modified:

17 May 2018 09:18

Publisher DOI:

10.1080/14737175.2017.1282821

PubMed ID:

28092989

Uncontrolled Keywords:

Complement Guillain-Barré syndrome Miller Fisher Syndrome eculizumab neuromyelitis optica

URI:

https://boris.unibe.ch/id/eprint/111508

Actions (login required)

Edit item Edit item
Provide Feedback